Menú

Inicio Revista Formación Noticias Agenda Categorías Quiénes Somos

Clinical stabilisation in neurodegenerative diseases: clinical study in phase II

E. de Font-Réaulx Rojas, G. Dorazco-Barragán Journal 50(09) ● Publication date 01/05/2010 ● Original ● Views 2185 ● Downloads 926 Castellano English

Download PDF
ESP Autoevaluación Add citation to
your library

Share this article on social networks:

Search in PubMed

By author

de Font-Reaulx Rojas E Dorazco-Barragan G

By keyword

Antiapoptotic Apoptosis Clinical stabilisation Neurodegenerative diseases

See in PubMed

Current article Related articles

Vea nuestros másteres

[REV NEUROL 2010;50:520-528] PMID: 20443170 DOI: https://doi.org/10.33588/rn.5009.2009546

INTRODUCTION. Neurodegenerative disorders, such as Parkinson’s disease (PD), Alzheimer’s disease (AD) and multiple sclerosis (MS), are progressive pathological conditions in which current treatments have not proved to be effective at curbing their progress (clinical stabilisation). Although they have very different clinical characteristics, they share the same pathophysiological mechanisms of progression. We developed a compound designed to obtain clinical stabilisation which acts by controlling cell damage due to aberrant apoptosis, oxidation, abnormal deposits of metals and proteins, and pathophysiological enzymatic pathways, such as that of caspases and the MAPK system.

PATIENTS AND METHODS. Forty-two patients with AD, PD and MS were included in the study. The compound was administered to them every 12 hours and they were given appointments every three months for a clinical evaluation and a review of general lab analyses.

RESULTS. Subjects were submitted to a follow-up of between 3 and 24 months (mean: 8.85 ± 5.99 months). No clinical side effects were recorded and there were only some slight alterations in the lab test results, although they were not clinically relevant. Clinical stabilisation was achieved in all the patients (100%) with MS and the scores on the Expanded Disability Status Scale improved in four patients (40%); clinical stabilisation in 17 patients (100%) with PD and improvements in the score on the Unified Parkinson’s Disease Rating Scale in 15 of them (88.2%); and clinical stabilisation in 12 patients (100%) with AD, and an increase in the score obtained on the minimental test in nine cases (75%).

CONCLUSIONS. The compound is safe and a promising therapeutic option, since there is a clear tendency towards clinical stabilisation when it is being used. An experimental study needs to be conducted in order to determine the therapeutic scope of the compound and its possible preventive effects, as well as to evaluate other indications.

Keywords Antiapoptotic Apoptosis Clinical stabilisation Neurodegenerative diseases Classified in Neurodegeneración

Search in PubMed

By author

de Font-Reaulx Rojas E Dorazco-Barragan G

By keyword

Antiapoptotic Apoptosis Clinical stabilisation Neurodegenerative diseases

See in PubMed

Current article Related articles

Search in PubMed

By author

de Font-Reaulx Rojas E Dorazco-Barragan G

By keyword

Antiapoptotic Apoptosis Clinical stabilisation Neurodegenerative diseases

See in PubMed

Current article Related articles

Clinical stabilisation in neurodegenerative diseases: clinical study in phase II

Share this article on social networks:

Search in PubMed

By author

By keyword

See in PubMed

Abierta la Matrícula

Máster en Sueño: Fisiología y Medicina

15ª Edición

Search in PubMed

By author

By keyword

See in PubMed

Search in PubMed

By author

By keyword

See in PubMed